Effects of Low-Level Laser Therapy on Oxidative Stress Levels

Summary

Hashimoto's thyroiditis (HT) is the most commonly observed inflammatory and autoimmune disease of the thyroid gland. Recent evidence has suggested that low-level laser therapy (LLLT) can improve thyroid function and reduce levels of thyroid peroxidase antibodies (TPOAb) in patients with hypothyroidism caused by chronic autoimmune thyroiditis. In the literature, data examining the effects of LLLT on oxidative stress level and quality of life in patients with HT is limited. The aim of the study is to examine the effects of LT4 treatment combined with LLLT on thyroid autoimmunity, oxidative stress and quality of life in patients with Hashimoto's diagnosis.

Conditions

• Hashimoto Thyroiditis
• Autoimmune Thyroiditis
• Thyroiditis
• Thyroid Diseases
• Autoimmune Diseases

Interventions

OTHER

Low Level Laser Therapy

Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.

OTHER

Sham

Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.

Sponsors & Collaborators

• Istanbul Medipol University Hospital

  lead OTHER

Principal Investigators

• Şükriye Leyla ALTUNTAŞ · Medipol University

• Murat ATMACA · Medipol University

• Sümeyye TUNÇ · Medipol University

• Çağrı ÇAKICI · Medipol University

• Türkan YİĞİTBAŞI · Medipol University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-02-09

Primary Completion

2022-04-15

Completion

2022-06-30

Countries

• Turkey (Türkiye)

Study Locations